The Week

Sarepta Therap (SRPT) closed the week at $18.67, down 7.16%, while the S&P 500 gained 1.21%, leaving SRPT about 8.37 percentage points behind the benchmark. The move was a rally-and-fade: Monday opened near $20.29, Tuesday touched a weekly high of $21.185, then Wednesday dropped from $20.72 to $18.95. Thursday and Friday traded in a range between $18.015 and $19.14, ending at $18.67. Weekly amplitude was 15.62%, and average daily volume of 2.5m shares ran 12.5% below the 60-day median.

Key Events

The week centred on Elevidys patent and real-world data. On 24 September, Regenxbio and Sarepta settled AAVrh74-related patent disputes with the University of Pennsylvania for $39m, with Sarepta to pay within 10 days of the effective date. The same day, Sarepta presented the first Phase 4 ENDURE real-world safety data for Elevidys in Duchenne muscular dystrophy patients at NMSG 2026. On 25 September, the company announced presentations at the 2026 World Muscle Society Annual Congress. Earlier in the week, trade press also noted Sarepta’s Q2 revenue surge alongside argenx in the gene and immunotherapy pipeline discussion.

Analyst Ratings

Of 23 brokers covering Sarepta, 7 rate it strong buy, 11 hold, 3 sell and 2 underweight. The consensus is hold, with a target of $21.86, about 17.1% above the current price of $18.67. The target range spans $5 to $38, more than sixfold apart, pointing to wide dispersion in valuation views. Among 506 biotech peers, Sarepta ranks 15th, above the industry median rank of 6.

The Week Ahead

On Monday and Tuesday, the US will release Dallas Fed manufacturing activity, FHFA house prices, Case Shiller 20-city home prices, JOLTS job openings and consumer confidence. Beyond macro data, follow-ups on the Phase 4 ENDURE real-world safety readout and further disclosures ahead of the World Muscle Society congress could keep driving risk appetite in the name.

In Short

SRPT pulled back this week while the S&P 500 advanced, with news flow centred on a patent settlement and Elevidys real-world safety data. Broker ratings are mixed: the consensus sits at hold, but the consensus target is 17.1% above spot, while the wide target range reflects valuation disagreement. The company runs a negative P/E with PB near 1.29x, and the latest session showed net selling in large-lot flow. Ahead, the focus turns to detailed data interpretation and macro readthroughs for biotech risk appetite.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.